Patent Expiry

Patent/Exclusivity Expiry: KHAPZORY

March 25, 2039

Company: Inhibrx Biosciences, Inc. (INBX)
Drug: KHAPZORY

Other upcoming events for INBX

Phase 3 ReadoutPhase 3 Topline: A Phase 2/3, Randomized Study of INBRX-106 Combined With Pembrolizumab Versus Pembrolizumab as First

Patent ExpiryPatent/Exclusivity Expiry: VYKOURA

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar